BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32608200)

  • 1. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer.
    Chang JY; Kim JH; Kang J; Park Y; Park SJ; Cheon JH; Kim WH; Kim H; Park JJ; Kim TI
    Yonsei Med J; 2020 Jul; 61(7):572-578. PubMed ID: 32608200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cancer stem cells from different grades of human colorectal cancer.
    Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
    Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
    Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
    Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
    Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
    Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
    J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
    Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
    Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
    Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
    Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
    Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
    Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of aberrant mTOR activation in patients with stage II and III colorectal cancer.
    Zhang TT; Zhu YQ; Cai HQ; Zheng JW; Hao JJ; Chang C; Cai Y; Wang MR; Liang JW; Zhang Y
    Biomark Med; 2020 Aug; 14(12):1127-1137. PubMed ID: 32969244
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and β-catenin in the prediction of prognosis and metastasis in colorectal carcinoma.
    Wu Q; Yang Y; Wu S; Li W; Zhang N; Dong X; Ou Y
    Diagn Pathol; 2015 Sep; 10():176. PubMed ID: 26408312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem Cell Marker Expression in Early Stage Colorectal Cancer is Associated with Recurrent Intestinal Neoplasia.
    Walker BS; Zarour LR; Wieghard N; Gallagher AC; Swain JR; Weinmann S; Lanciault C; Billingsley K; Tsikitis VL; Wong MH
    World J Surg; 2020 Oct; 44(10):3501-3509. PubMed ID: 32647988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
    Michl M; Heinemann V; Jung A; Engel J; Kirchner T; Neumann J
    Pathol Res Pract; 2015 Aug; 211(8):601-9. PubMed ID: 26092596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer.
    Gzil A; Zarębska I; Jaworski D; Antosik P; Durślewicz J; Maciejewska J; Domanowska E; Skoczylas-Makowska N; Ahmadi N; Grzanka D; Szylberg Ł
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2547-2557. PubMed ID: 32671503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
    Wang D; Fu L; Sun H; Guo L; DuBois RN
    Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMOC2, an intestinal stem cell marker, is an independent prognostic marker associated with better survival in colorectal cancers.
    Jang BG; Kim HS; Bae JM; Kim WH; Kim HU; Kang GH
    Sci Rep; 2020 Sep; 10(1):14591. PubMed ID: 32884102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between markers of colorectal cancer stem cells and adenomas among ethnic groups.
    Leavell BJ; Van Buren E; Antaki F; Axelrod BN; Rambus MA; Majumdar AP
    Dig Dis Sci; 2012 Sep; 57(9):2334-9. PubMed ID: 22562538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance.
    Choi JE; Bae JS; Kang MJ; Chung MJ; Jang KY; Park HS; Moon WS
    Oncol Rep; 2017 Sep; 38(3):1695-1705. PubMed ID: 28677737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma.
    Yan M; Yang X; Wang L; Clark D; Zuo H; Ye D; Chen W; Zhang P
    Mol Cell Proteomics; 2013 Nov; 12(11):3271-84. PubMed ID: 23903875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.